1- [(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)amino]benzotriazole-5-carboxylic acid (CBt-PMN), a partial agonist of retinoid X receptor (RXR), has attracted attention due to its potential to treat type 2 diabetes and central nervous system diseases with reduced adverse effects of existing full agonists. Herein, we report the crystal structure of CBt-PMNbound ligand-binding domain of human RXRa (hRXRa) and its biochemical characterization. Interestingly, the structure is a tetramer in nature, in which CBt-PMNs are clearly found binding in two different conformations. The dynamics of the hRXRa/CBt-PMN complex examined using molecular dynamics simulations suggest that the flexibility of the AF-2 interface depends on the conformation of the ligand. These facts reveal that the dual conformation of CBt-PMN in the complex is probably the reason behind its partial agonistic activity.
Retinoid X receptor (RXR) is a member of nuclear receptor (NR) superfamily, which regulates various physiological metabolism, such as dietary lipid metabolism [1] and nervous system [2] , via forming homodimer or heterodimers with other NRs [3] . Binding of small molecules to the ligand-binding pocket (LBP) induces the conformational change of 'AF-2 interface', which plays a key role in recognizing the L XX LL motifs located in coactivators [4] [5] [6] . Although various agonists targeting RXR have been developed [7] , it has been shown that they cause unwanted adverse effects such as elevation of blood triglyceride [8, 9] , weight gain [10] , hepatomegaly [10, 11] , and hypothyroidism [12] . Recently, we have designed and synthesized a RXR partial agonist, 1-[ (3,5,5,8,8-pentamethyl-5,6,7,8- tetrahydronaphthalen-2-yl)amino]benzotriazole-5-carboxylic acid (CBt-PMN, Fig. 1A ) [13] . Subsequently, we have shown that this partial agonist has potent glucose lowering and improved insulin secretion and glucose tolerance effects without causing any serious adverse effects in type 2 diabetes model mice [13, 14] . Besides, we have recently shown that the CBt-PMN could be a candidate for the treatment of central nervous system (CNS)-related diseases [15] . Yet, the molecular basis behind its partial agonistic nature toward RXR is completely unknown.
Crystal structures of apo and various modulatorbound ligand-binding domain (LBD) of human RXRa (hRXRa) were reported in the past [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . They can largely be classified into two types according to their conformation of the AF-2 interface in the C-terminal region; the 'folded' or 'extended' form. The agonistbound RXR complexes mostly appear in the 'folded' form [18, 20, 22] , although the existence of this complex in 'extended' form was also found in some cases, such as in an endogenous ligand 9-cis-retinoic acid (9cRA)-bound RXR complex, where the LBP of only some subunits are occupied by the ligand [17] . The apo [17, 21] and a few other selectively bound ligated RXR structures [17, 21, 23, 24] were found in the 'extended' form. This is also true with the antagonist danthronbound hRXRa-LBD [21] . In these 'extended' forms, the hRXRa-LBD forms a tetramer, which is stabilized by packing of C-terminal helix containing the L XX LLlike motif ( 451 LMEML 455 ) with the coactivator binding groove of the neighboring molecule [17] . The formation of this tetrameric state is a unique feature of hRXRa-LBD and has not been observed in other NRs [26] . Thus, the binding of agonists transforms the nature of hRXRa-LBD from tetramer to dimer form whereas that of antagonists does not influence the oligomeric state. Meanwhile, hRXRa-LBD bound to partial agonists have been shown to have a dimer form with a 'folded' AF-2 interface [19, 25] , similar to that of the typical agonist-bound structure. Unfortunately, the dynamics of the AF-2 interface, whose conformation plays the most important role in the transactivity of RXR, remains not completely clear although a few studies in the past made considerable progress [19, 27, 28] .
Here, we studied the structure and biomolecular mechanism of CBt-PMN-bound hRXRa complex by combining crystallographic, biochemical, and computational analysis. The study explored the origin of the partial agonistic activity of CBt-PMN through the dynamics of the AF-2 interface. Particular importance is given to understand the difference in mechanism between CBt-PMN-and a full agonist bexarotenebound hRXRa complexes (see Fig. 1A , bexarotene).
Materials and methods

Ligands and fluorescein peptides
CBt-PMN and bexarotene were synthesized as shown in references [13, 29] , respectively. PA452 was kindly provided by Prof. Hiroyuki Kagechika of Tokyo Medical and Dental University [30] [31] [32] . COS-1 cells were purchased from RIKEN BRC Cell Bank (RCB0143, Japan). Non-fluorescein-labeled peptide derived from SRC 1 (687-HKILHRLLQEGS-698) for SEC were purchased from Genscript. Fluorescein-labeled peptide derived from SRC 1-2 for a fluorescent polarization assay were purchased from Thermo Fisher Scientific Inc. (USA).
Protein expression and purification
The 6-histidine-tagged hRXRa-LBD (residues 224-462 and 227-462) were expressed in Escherichia coli BL21 (DE3) using pET28a and pET15b plasmid vector, respectively. Cells were cultured with 0.5 mM of isopropyl b-D -thiogalactopyranoside at 310 K, and harvested after 3-5 h. Purification was performed as described previously [19] . Cells were resuspended in 20 mM Tris-HCl (pH 8.0), 500 mM NaCl, 5 mM imidazole at 277 K, and lysed by ultrasonication. Insoluble debris was removed by centrifugation at 48 400 g for 30 min. hRXRa proteins were partially purified by nickel-nitriloacetic acid resin prepack (GE Healthcare, Chicago, IL, USA), following further purification by a Superdex 200 size exclusion chromatography (SEC) pre-equilibrated with 10 mM Tris-HCl (pH 7.5), 150 mM NaCl, 5 mM DTT. His tag of hRXRa-LBD (224-462) was cleaved before SEC, whereas that of hRXRa-LBD (227-462) was not cleaved. The concentration of the purified hRXRa-LBD (224-462 and 227-462) was determined by a molar extinction coefficient of 16 500 M
À1
Ácm
À1 at 280 nm.
Reporter gene assay
Luciferase reporter gene assays using COS-1 cells were performed as described previously [13] . Briefly, COS-1 cells were transfected with three kinds of vectors consisting of a hRXRa, a luciferase reporter gene under the control of the appropriate RXR response element (CRBPII-tk-Luc), and secreted alkaline phosphatase (SEAP) gene as a background. Test compound solutions (1% DMSO) were added to the suspension of transfected cells, which were seeded at about 2.0 9 10 4 cells/well in 96-well white plates. After incubation in a humidified atmosphere of 5% CO 2 at 310 K for 24 h, 25 lL of the medium was used for analyzing SEAP activities and the remaining cells were used for luciferase reporter gene assays with a Steady-Glo Luciferase Assay system (Promega, Madison, WI, USA) according to the supplier's protocol. The luciferase activities were normalized using SEAP activities. The assays were carried out in triplicate. Data are the mean SEM (n = 3). The results are normalized to the induction observed with 1 lM bexarotene.
Fluorescence polarization assay
A fluorescence polarization assay was performed as reported previously [33] . The buffer containing 10 mM HEPES (pH 7.9), 150 mM NaCl, 2 mM MgCl 2 , 5 mM DTT, 1% DMSO (not considering DMSO dissolving fluorescein peptides) was utilized. Black 384-well microplates were purchased from Greiner Bio-One International (#784076). The final concentration of hRXRa-LBD (227-462) was 0.5, 1, 5, and 10 lM, respectively. The final concentration of fluorescein-labeled peptide and compound are 10 nM and 10 lM, respectively. hRXRa-LBD, fluorescein-labeled peptide, and compound were diluted to two-, four-, or fourfold, respectively, higher concentration than the final concentrations by using the assay buffer described above. A quantity of 5 lL of fluorescein-labeled peptide (40 nM) was added to four wells containing 10 lL of hRXRa-LBD at each concentration of twofold higher concentration than the final concentration and 5 lL of compound solution at 40 lM (containing 4% DMSO). After incubation at room temperature (295-298 K) for 2 h, fluorescence polarization (mP) was measured at k ex = 485 nm and k em = 535 nm using a TECAN polarion plate reader (G-factor = 0.91).
Size exclusion chromatography
Size exclusion chromatography analysis was performed to determine apparent molecular weights using a Superdex 200 pg increase column (GE Healthcare) with a flow rate of 0.2 mLÁmin À1 . The hRXR-LBD (227-462) of 108 lM in 20 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.5 mM tris(2-carboxyethyl)phosphine, 5% glycerol, and 10% DMSO were used. Before injecting on the column, protein solution was incubated with 1 mM CBt-PMN and/or 500 lM SRC1 peptide for an hour.
Cocrystallization of binary RXR-LBD/CBt-PMN complex
The stock solution of CBt-PMN was prepared by dissolving in 100% DMSO at the final concentration of 100 mM. 
Data collection and structure solution
Prior to data collection, the crystals were soaked in a cryoprotectant solution containing 20% glycerol along with the reservoir buffers, and flash-frozen using liquid nitrogen or nitrogen gas stream at 95 K. X-ray diffraction experiments were performed at the beamlines BL26B1 and 38B1 at SPring-8 and BL-1A and 5A at KEK-PF, Japan. Data were processed and scaled using XDS [34] and truncated by the CCP4 program suite [35] . The initial phases were determined by the molecular replacement method using the program PHASER [36] with the structures of the tetrameric RXRa-LBD (PDB ID: 4N8R) [23] as a search model. Several cycles of manual model rebuilding by using Coot [37] and refinements by using REFMAC [38] and PHENIX [39] were performed. The initial model and parameter file for CBt-PMN were prepared by PRODRG server [40] . The refined models were validated by MOLPROBITY [41] . The statistics for data collection and refinement are summarized in Table S2 .
Protein structure accession number
Crystal structure has been deposited in the Protein Data Bank (accession code 5ZQU). All figures were prepared using PYMOL software (W. L. Delano; http://www.pymol.org/).
System setup of RXRa/ligand complexes for in silico analysis
Crystal structure of a hRXRa/CBt-PMN complex was protonated by the Protonate3D [42] and N-terminal residue and C-terminal residue were capped by the acetyl group (ACE) and the N-methyl amide group (NME), respectively, by using molecular operating environment (MOE) program [43] . Energy minimization of the structure was performed using Amber 10 (EHT force field, Born solvation and 0.001 kcalÁmol À1 A À2 root means square gradient).
Molecular dynamics simulations
For molecular dynamics (MD) simulations, the hRXRa/ CBt-PMN complex structure was solvated with water molecules and the necessary counter ions were added to neutralize the system using tleap module in AMBER 14 software [44] . AMBER14SB force field [45] for proteins, the generalized amber force field [46] and AM1-BCC atomic charge [47] for ligands, and TIP3P water model for the solvent water were used. All the MD simulations were performed with GROMACS software [48] . The complex system was subjected to simulations up to 350 ns at 300 K and a pressure of 1 bar, with the NPT ensemble.
Results
CBt-PMN acts as a partial agonist of hRXRa
It is observed in cell analysis that the relative transcriptional activity of CBt-PMN is about half of that of bexarotene, indicating that the CBt-PMN acts as a partial agonist in COS-1 cell (Fig. 1B) . The cofactor recruitment assay (Fig. 1C ) also supports the results of the in cell assay; the recruitment of coactivator (SRC1-2)-derived peptides by hRXRa/CBt-PMN is lower than that by the agonist bexarotene-bound hRXRa, but higher than that by the antagonist PA452-bound hRXRa in the conditions containing 5 and 10 lM of RXRa-LBD. Hence, these results clearly indicate that CBt-PMN acts as a partial agonist of hRXRa, strengthening our earlier conclusions [13, 49] .
Interaction analysis between hRXRa-LBD and CBt-PMN
Size exclusion chromatography analysis indicates that hRXRa-LBD exists primarily in the tetramer form (Fig. 1D ), but both tetramer and dimer forms, in approximately equal amounts, are formed upon the binding of CBt-PMN (Fig. 1D) . The study also reveals that the SRC1 binding to hRXRa/CBt-PMN turns this complex primarily to the dimer form (Fig. 1D) . Thus, it is clear that CBt-PMN stabilizes the hRXRa in both dimer and tetramer forms but the coactivator recruitment induces a tetramer-to-dimer transformation and stabilizes the hRXRa/CBt-PMN/SRC1 complex in the dimer form. The binding affinity of CBt-PMN to hRXRa-LBD estimated by isothermal titration calorimetry (ITC) implies that the complex formation is an exothermic one; the calculated dissociation constant (K d ) is 7.0 AE 1.2 lM. ITC spectra and thermodynamic parameters are given in Fig. S1A and Table S1 . We employed CD spectroscopy to monitor structural change in solution and the CD intensity at 222 nm is slightly elevated (Fig. S1B) by the binding of CBt-PMN. This shift indicates a moderate extension of a-helix upon the binding of CBt-PMN.
Crystal structure of hRXRa-LBD/CBt-PMN complex
The crystal structure of hRXRa-LBD complexed with CBt-PMN has been determined at 2.6-A resolution ( Fig. 2A, Table S2 ). Unexpectedly, the structure is similar to the known tetrameric form apo hRXRa-LBD structure (e.g., PDB code: 1G1U) [17] : the RMSD value for Ca atoms is 0.90 A. Unlike partly ligated tetrameric complexes reported previously, all of the subunits show clear electron density corresponding to the ligand in their LBP (Fig. 2B) . The ligand electron density is also observed in the interface between subunits A1 and B2, and between subunits B1 and A2 (Fig. S2) , resulting six units of the CBt-PMN bound to the tetramer hRXRa (Fig. 2A) . The biological implication of these secondary binding sites is not clear at present. Another significant point in our structure is that the C-terminal helix in all the subunits is in extended form, similar to that in the apo structure.
Structural comparison between the subunits reveals two types of ligand binding in hRXRa/CBt-PMN: one is observed in subunits A1 and A2 (Type A) and the other is observed in subunits B1 and B2 (Type B) (Fig. S3) . The tetrahydronaphthalene ring of CBt-PMN adopts two different conformations along the C-N bond (Fig. 2C) . Although the difference in orientation slightly shifts the carboxyl group in subunit B (Fig. S4) , its hydrogen bonding interactions with R316 and A327 residues are similar in all the subunits as well as those in the other hRXRa crystal structures ligated with 9cRA [20] , and bexarotene [22] . In contrast to this similarity, the interactions with the hydrophobic moiety of the CBt-PMN (Fig. 2C) are different between subunits A and B due to the difference in the ligand conformation and subsequently the LBP orientation.
Superposition of the CBt-PMN in our structure and bexarotene reveals that the alignment of the tetrahydronaphthalene ring of CBt-PMN in subunits A is similar to that of bexarotene, though the conformation of the C-terminal helix in these complexes differs, whereas the same ring has an opposite orientation in subunits B (Fig. 2D) . So it is clear that the hRXRa/ CBt-PMN has two different binding modes (Fig. 3) . CH-p interaction exists between L309 and tetrahydronaphthalene ring in subunits A is absent in subunits B. Similarly, the hydrophobic interactions between F439 and I442 with the same ring moiety in subunits B are almost nil in subunits A. The interaction energies calculated using quantum mechanical fragment molecular orbital (FMO) theory support these experimental findings quantitatively (Fig. S5) .
MD simulation for AF-2 interface of hRXRa-LBD/ CBt-PMN complex
Molecular dynamics simulations were performed on hRXRa-LBD/CBt-PMN complex to understand the influence of ligand binding to the structural changes, especially in the C-terminal region. It is shown that the structures of subunits A1 and B1, in general, are retained all along the 350-ns trajectory, except in the C-terminal regions (Figs 4 and S6) . The C-terminal region in subunit A1 rapidly forms a folded structure (Fig. 4) , suggesting that the ligand binding induces the formation of folded C-terminal region that would facilitate RXR to recruit a coactivator. Contrarily, the C-terminal helix in subunit B1 stays predominantly an extended structure with a large flexibility (Fig. 4) despite the presence of bound ligand, indicating that the difference in the binding mode of the ligand could affect the recruitment of the coactivator. The structural difference in the C-terminal region also correlates with the conclusions made in a study using fluorescence anisotropy that the addition of a partial agonist decreases anisotropy corresponding to the increase in mobility of helix 12 [19] .
Discussion
The binding of agonists to NRs induces the structural changes in the C-terminal region, especially in helix 12, and bring it to the folded form to recruit a coactivator efficiently [6] , whereas an antagonist binding stabilizes the same region in the extended form by establishing a tetrameric structure [21] . Unlike a 'folded' type homodimer structure identified for a partial agonist-bound hRXRa-LBD in a recent study [25] , the crystal structure of the hRXRa-LBD/CBt-PMN complex reported here has a tetrameric structure with an extended form of C-terminal helix with the ligand in two different rotational conformations. The conformation of CBt-PMN in subunit A1 is similar to that of bexarotene in the 'folded' form of hRXRa and the MD simulations clearly indicate that the conformation of the C-terminal helix changes to the folded form immediately in this subunit (Fig. 4) . On the other hand, the same helix in subunit B1, in which CBt-PMN exists in a different conformation is unlikely to move to the folded form. The C-terminal region in subunit B1 fluctuates significantly but nevertheless keeps its extended nature predominantly (Fig. 4) . Thus, subunit A1 is likely to represent agonistic interaction between CBt-PMN and hRXRa, like that between bexarotene and hRXRa, whereas subunit B1 represents antagonistic one. The rotation around the CBt-PMN C-N bond, which distinguishes the two conformations of CBt-PMN, might have a large barrier due to the presence of bulky hydrophobic residues that could cause large steric hindrance to the LBP. If so, conversion between the two conformations of the ligand would rather be difficult in the LBP, and consequently, the bound CBt-PMN in the subunit B1 stabilizes an extended form C-terminal helix in spite of a large perturbation at the C-terminal region. Taken together, our crystal structure and MD simulations strongly suggest that the partial agonistic nature of CBt-PMN comes from its ability to bind to hRXRa in two different binding modes that stabilize the C-terminal region either in the folded or extended form.
Our SEC results support the above fact that the complex exists in approximately equivalent amounts of dimer and tetramer. There is a possibility that the stabilization of the extended form by CBt-PMN might not be so strong, and therefore, the addition of excess SRC1 peptide could cause the equilibrium shift toward the dimer (i.e., C-terminal folded) form. This supports our above theory that the stabilization of both extended and folded forms of the C-terminal region due to the multiple conformation of CBt-PMN promotes a moderate equilibrium between extended and folded forms, and induces the partial agonistic activity for hRXRa.
In conclusion, we solved the crystal structure of hRXRa-LBD/CBt-PMN and investigated the origin of its partial agonistic activity through experimental and in silico approaches. The ability of CBt-PMN to bind to the LBP of hRXRa in two different binding modes induces the existence of C terminus in both extended and folded forms, resulting in reduced formation of the activated AF-2 interface. Our findings provide useful new insights that may lead to rational design of partial agonists targeting NRs to replace the existing drugs with serious adverse effects.
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